Clinical Trial Update: SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating SITAgliptin plus GLARgine for glycemic control in hospitalized Type 2 diabetes patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glargine (insulin glargine)
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED